Skip to main content
SpringerLink
Log in

Peroxisome proliferator-activated receptor γ Pro12 ala polymorphism and risk of cerebral stroke in type 2 diabetes mellitus egyptian patients

  • Research article
  • Published:
Journal of Diabetes & Metabolic Disorders Aims and scope Submit manuscript

Abstract

Objectives

This study aimed to analyze the association of the peroxisome proliferator activated receptor gamma (PPARγ) P12A (rs1801282) polymorphism with development of cerebral stroke in patients with type 2 diabetes mellitus.

Methods

We included 224 patients with diabetes, they were categorized into116 patients with ischemic stroke (IS) and 108 without IS, in addition to 148 healthy controls in this study. respectively. Anthropometric parameters and laboratory tests were measured. The polymorphism was detected by a PCR-RFLP method.

Results

A12 allele and A12 containing genotypes show significant higher percentage in patients with diabetes and IS in comparison to diabetes patients without IS (9.1 vs. 4.2%,16.4 vs7.4%; P = 0.044,0.044) with OR of 2.29 and 2. 449 respectively (95% CI: 1.024–5.115, 1.024–5.856) but does not withstand Bonferroni correction.

Conclusion

A12 containing genotypes and A12 allele are not associated with IR, diabetes and risk of IS development, however, significant higher BMI were observed in A12 allele carriers in the studied patients with diabetes as well as those with IS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Quinn L. Type 2 diabetes: epidemiology, pathophysiology, and diagnosis. NursClin North Am. 2001;36(2):175–92.

    Article  CAS  Google Scholar 

  2. Bos M, Agyemang C. Prevalence and complications of diabetes mellitus in Northern Africa, a systematic review. BMC Public Health. 2013;13:387.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ergul A, Kelly-Cobbs A, Abdalla M, Fagan SC. Cerebrovascular complications of diabetes: Focus on Stroke. EndocrMetab Immune Disord Drug Targets. 2012;12(2):148–58.

    Article  CAS  Google Scholar 

  4. Arnett DK, Baird AE, Barkley RA, Basson CT, Boerwinkle E, Ganesh SK, et al. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 2007;115(22):2878–901.

    Article  PubMed  Google Scholar 

  5. Stumvoll M, Ha¨ring H. The peroxisome proliferator–activated receptor γ2 Pro12Ala polymorphism. Diabetes. 2002;51(8):2341–7.

    Article  CAS  PubMed  Google Scholar 

  6. Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006;26:28–40.

    Article  CAS  PubMed  Google Scholar 

  7. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun. 1997;241:270–4.

    Article  CAS  PubMed  Google Scholar 

  8. Kim SY, Kim HI, Park SK, Im SS, Li T, Cheon HG, et al. Liver glucokinase can be activated by peroxisome proliferatoractivated receptor-gamma. Diabetes. 2004;53(Suppl 1):66–70.

    Article  Google Scholar 

  9. Gonzalez JPM, Borrella CC, Mayoral R, Gudino LC, Hoghtower CM, Sarmiento RG. PPAR gamma pro12Ala polymorphism and type 2 diabetes: a study in a spanishcohort. J Genet Stud. 2014;2:1.

    Article  Google Scholar 

  10. Jin J, Ding G, Bao H, Chen Y, Han Y, Zhao F,et al. Correlation between PPAR gene polymorphisms and primary nephrotic syndrome in children. PPAR Res. 2013;ID 927915:1–8.

    Article  Google Scholar 

  11. Radha V, Vimaleswaran K, Narayan SH, Abate N, Chandalia M, Satija P, et al. Role of genetic polymorphism peroxisome proliferator–activated Receptor- γ 2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and caucasian subjects. Diabetes Care. 2006;29:1046–51.

    Article  CAS  PubMed  Google Scholar 

  12. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000;26:76–80.

    Article  CAS  PubMed  Google Scholar 

  13. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, et al. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. BiochemBiophys Res Commun. 2000;271:212–6.

    Article  CAS  Google Scholar 

  14. Scacchi R, Pinto A, Rickards O, Pacella A, De Stefano GF, Cannella C, et al. An analysis of peroxisome proliferator-activated receptor gamma (PPAR-gamma 2) Pro12Ala polymorphism distribution and prevalence of type 2 diabetes mellitus (T2DM) in world populations in relation to dietary habits. NutrMetabCardiovasc Dis. 2007;17:632–41.

    CAS  Google Scholar 

  15. Sarhangi N, Sharif F, Hashemian L, Doabsari MH, Heshmatzad K, Rahbaran M, et al. PPARG (Pro12Ala) genetic variant and risk ofT2DM: a systematic review and metaanalysis. Sci Rep. 2020;10:12764.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Wan J, Xiong S, Chao S, Xiao J, Ma Y, Wang J, Roy S. PPARg gene C161T substitution alters lipid profile in chinese patients with coronary artery disease and type 2 diabetes mellitus. Cardiovasc Diabetol. 2010;9:13.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Beyer AM, de Lange WJ, Halabi CM, Modrick ML, Keen HL, Faraci FM, et al. Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet. Circ Res. 2008;103:654–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Hsieh F-I, Wei-Cheng LO, Lin H-J, Hsieh Y-C, Lien L-W, Bai C-H, et al. Significant synergistic effect of peroxisome proliferator–activated receptor γ C-2821T and diabetes on the risk of ischemic stroke. Diabetes Care. 2009;32:2033–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Temelkova-Kurktschiev T, Hanefeld M, Chinetti G, et al. Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. J ClinEndocrinolMetab. 2004;89:4238–42.

    Article  CAS  Google Scholar 

  20. Al-Shali KZA, House AA, Anthony JG, Hanley AJG, Khan HMR, Harris SB, et al. Genetic variation in PPARG encoding peroxisome proliferator-activated receptor γ Associated with Carotid atherosclerosis. Stroke. 2004;35:2036–40.

    Article  CAS  PubMed  Google Scholar 

  21. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl. 1):81–90.

    Article  Google Scholar 

  22. National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the national cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002. 17;106(25):3143–421.

  23. Tangvarasittichai S, Poonsub P, Tangvarasittichai O. Association of serum lipoprotein ratios with insulin resistance in type 2 diabetes mellitus. Indian J Med Res. 2010;131:641–8.

    CAS  PubMed  Google Scholar 

  24. Ray S, Bairagi AK, Guha S, Ganguly S, Ray D, Basu AK, et al. A simple way to identify insulin resistance in non-diabetic acute coronary syndrome patients with impaired fasting glucose. Indian J EndocrinolMetab. 2012;16(Suppl 2):460–4. doi:https://doi.org/10.4103/2230-8210.104132: PMC3603115.

    Article  CAS  Google Scholar 

  25. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults,1999–2000. JAMA. 2002;288:1723–7.

    Article  PubMed  Google Scholar 

  26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. ClinChem. 1972;18(6):499–502.

    CAS  Google Scholar 

  27. Hermans MP, Sacks FM, Ahn SA, Rousseau MF. Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: discriminant ratio and unbiased equivalence. Cardiovasc Diabetol. 2011;10:20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J,et al. The Pro12 ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes. 2001;50:891–4.

    Article  CAS  PubMed  Google Scholar 

  29. No Association between Pro12Ala polymorphism in Peroxisome Proliferator Activated Receptor Gamma 2 gene. and type 2 diabetes in a Cameroonian population E.P. Mofo Mato a,c a,c, E. Sobngwi b,c,d, O. Donfack Sontsa a,c, E.N. Ndonwi a,c, M. Guewo Fokeng a,c, P. Fosso Pokam a,c, E. Djahmeni d, B. Atogho Tiedeu a,c, M.S. Evehe a,c, R. DjokamDadjeu a,c, F. Aminkeng e, W.F. Mbacham a,f, J.C. Mban.DIABETES RESEARCH A N D CLINICAL PRACTICE 103S (2 014) 103(1):S37-S38.

  30. Paramasivam D, Safi SZ, Qvist R, Bin ZainalAbidin I, Hairi NNM, Chinna K. Role of PPARG (Pro12Ala) in malaysian type 2 diabetes mellitus patients. Int J Diabetes DevCtries. 2016. https://doi.org/10.1007/s13410-015-0462-5.

    Article  Google Scholar 

  31. Iwata E, Yamamoto I, Motomura T, Tsubakimori S, Nohnen S, Ohmoto M, et al. The association of Pro12Ala polymorphism in PPARgamma2 with lower carotid artery IMT in japanese. Diabetes ResClinPract. 2003;62:55–9.

    CAS  Google Scholar 

  32. Ridker PM, Cook NR, Cheng S, Erlich HA, Lindpaintner K, Plutzky J, et al. Alanine for proline substitution in the peroxisome proliferatoractivated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. ArteriosclerThrombVasc Biol. 2003;23:859–63.

    Article  CAS  Google Scholar 

  33. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20:284–7.

    Article  CAS  PubMed  Google Scholar 

  34. Zafarmand MH, van der Schouw YT, Grobbee DE, de Leeuw PW, Bots ML. Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction,coronary heart disease and ischemic stroke: a case cohort study and meta-analyses. Vasc Health Risk Manag. 2008;4:427–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Hsieh FI, Lo WC, Lin HJ, Hsieh YC, Lien LM, Bai CH. e al. Significant synergistic effect of peroxisome proliferator–activated receptor gamma c-2821t and diabetes on the risk of ischemic stroke. Diabetes Care. 2009;32:2033–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Lee BC, Lee HJ, Chung JH. Peroxisome proliferator- activated receptor- γ 2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes. Neurosci Lett. 2006;410:141–5.

    Article  CAS  PubMed  Google Scholar 

  37. Wang YZ, Zhang HY, Liu F, Li L, Deng SM, He ZY. Association between PPARG genetic polymorphisms and ischemic stroke risk in a northern Chinese Han population: a case-control study. Neural Regen Res,2019; 14(11):1986–1993. https://doi.org/10.4103/1673-5374.259621.

  38. Tai ES, Corella D, Deurenberg-Yap M, Adiconis X, Chew SK, Tan CE, et al Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res 2004;45:674–85.

  39. Mansoori A, Amini M, Kolahdooz F, Seyedrezazadeh E. Obesity and Pro12Ala Polymorphism of Peroxisome Proliferator-Activated Receptor-Gamma Gene in Healthy Adults: A Systematic Review and Meta-Analysis. Ann Nutr Metab 2015;67:104–118. https://doi.org/10.1159/000439285.

  40. Mancini FP, Vaccaro O, Sabatino L, Tufano A, Rivellese AA, Riccardi G, et al Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. Diabetes 1999; 48: 1466–1468.

  41. Bouhaha R, Meyre D, Kamoun HA, Ennafaa H, Vaillant E, Sassi R, et al Effect of ENPP1/PC-1-K121Q and PPARgamma-Pro12Ala polymorphisms on the genetic susceptibility to T2D in the Tunisian population. Diabetes Res ClinPract 2008; 81:278–283.

  42. Kolehmainen M, Uusitupa MI, Alhava E, Laakso M, Vidal H. Effect of the Pro12Ala polymorphism in the peroxisome proliferator-activated receptor (PPAR) gamma2 gene on the expression of PPARgamma target genes in adipose tissue of massively obese subjects. J Clin Endocrinol Metab 2003; 88:1717–1722.

  43. Hegele Cao RA, Harris H, Zinman SB, Hanley B, Anderson AJ CM. Peroxisome proliferator-activated receptor-gamma2 P12A and type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab 2000; 85:2014–9.

  44. Meirhaeghe Amouyel A, P. Impact of genetic variation of PPAR in humans.Mol Genet Metab. 2004;83:93–102.

  45. Oh EY, Min, Chung KM, Min JH, Lee YK, Kim MS KW,et al. Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-gamma2 in Korean diabetic and obese subjects. J Clin Endocrinol Metab 2000;85:1801–4.

  46. Soriguer F1, Morcillo Cardona S, Rojo-Martínez F, G, de la Cruz Almaráz M, Ruiz de Adana Mde L, et al. Pro12Ala Polymorphism of the PPARG2 Gene Is Associated with Type 2 Diabetes Mellitus and Peripheral Insulin Sensitivity in a Population with a High Intake of Oleic Acid. J Nutr 2006; 136: 2325–2330.

  47. Okita k, Iwahashi H, Kozawa J, Okauchi Y, Funahashi T, Imagawa A, et al. Homeostasis model assessment of insulin resistance for evaluating insulin sensitivity in patients with type 2 diabetes on insulin therapy. Endocr J 2013; 60 (3): 283–290.

  48. McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol. 2005;1(3):399–404. 96.

    Article  Google Scholar 

  49. Zietz B, Barth N, Spiegel D, Schmitz G, Scholmerich J, Schaffler A. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 (PPARgamma2) is associated with higher levels of total cholesterol and LDL-cholesterol in male caucasian type 2 diabetes patients. Exp Clin Endocrinol Diabetes. 2002;110:60–6.

    Article  CAS  PubMed  Google Scholar 

  50. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Auwerx J, Deeb SS, et al. Impact of the peroxisome proliferator activated receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disor. 2000;24:195–9.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank Dr. Ekbal Abohashem, Professor.

of clinical pathology for her contribution in manuscript revision.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Author information

Authors and Affiliations

  1. Clinical Pathology department, Mansoura University Faculty of Medicine, Elgomhouria St, 35516, Mansoura City, Egypt

    Reham M. El-Farahaty, Amany EL-Deasty & Narmin Saied

  2. Internal Medicine department, Mansoura University Faculty of Medicine, Elgomhouria St, 35516, Mansoura City, Egypt

    Osama Fouda

  3. Public health department, Mansoura University Faculty of Medicine, Elgomhouria St, 35516, Mansoura City, Egypt

    Abdel-Hady El-Gilany

Authors
  1. Reham M. El-Farahaty
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Osama Fouda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amany EL-Deasty
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abdel-Hady El-Gilany
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Narmin Saied
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

RME, NS & AE: Study design, laboratory analysis, acquisition of data & interpretation of the results. OF: Original idea, patient characterisation and diagnosis. AE: Data and statistical analyses. RME: writing the manuscript. All authors read and accepted the final manuscript.

Corresponding author

Correspondence to Narmin Saied.

Ethics declarations

Declaration of interests:

None of the authors declared conflict of interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El-Farahaty, R.M., Fouda, O., EL-Deasty, A. et al. Peroxisome proliferator-activated receptor γ Pro12 ala polymorphism and risk of cerebral stroke in type 2 diabetes mellitus egyptian patients. J Diabetes Metab Disord 22, 415–422 (2023). https://doi.org/10.1007/s40200-022-01159-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40200-022-01159-0

Keywords

Search

Navigation